For the first time in decades, the European Union is undertaking a major overhaul of its pharmaceutical legislation.
The European Commission’s new “Pharma Law Package”, adopted by the Council of the European Union in June 2025, profoundly reshapes the regulatory, economic, and scientific landscape of the European drug market.
This European new pharmaceutical legislation aims to make the market more competitive while ensuring fair and rapid access to innovation across all EU member states. Lessons learned from the Covid-19 pandemic have also prompted the EU to strengthen the resilience of its pharmaceutical system.
For clinical and regulatory stakeholders — pharmaceutical companies, CROs, EU representatives, and academic sponsors — this marks a turning point that must be anticipated now.
European new pharmaceutical legislation to reconcile innovation and equitable access
The main objectives of this European new pharmaceutical legislation are clear:
- Stimulate innovation by simplifying procedures and cutting bureaucracy;
- Ensure faster and more uniform access to medicines for all European patients;
- Prevent drug shortages and improve supply chain resilience;
- Reinforce Europe’s global influence in health and life sciences.
The reform introduces a new modular model of regulatory data protection rights.
Under the current “8 + 2 (+1)” system, marketing authorization holders benefit from:
- 8 years of data exclusivity,
- 2 years of market exclusivity,
- And 1 additional year for a new therapeutic indication providing significant clinical benefit.
During this period, the data package supporting the marketing authorization cannot be used by generic or biosimilar manufacturers for their own applications.
With up to 11 years of protection, the EU currently offers the world’s longest period of regulatory exclusivity for medicines.
However, experts remain divided over whether such lengthy protection genuinely fosters R&D investment within the EU or, conversely, slows competition and access to affordable treatments.
Extended exclusivity also carries major budgetary implications for member states: generics and biosimilars can only enter the market once all protections expire.
Toward conditional protection: rewarding innovation through access and evidence
The new European pharmaceutical reform introduces a conditional and performance-based protection system.
The Commission proposes reducing the baseline data exclusivity from eight to six years, while allowing companies to earn additional protection through a set of measurable criteria.
The underlying principle: not all innovative medicines deserve the same protection period.
Regulatory exclusivity becomes an incentive tool, granted based on the manufacturer’s ability to demonstrate real-world clinical value and responsible market behavior.
A company could earn extensions of exclusivity if it:
- Submits comparative clinical trial data proving therapeutic superiority over existing treatments;
- Addresses an unmet medical need for a rare or severe disease;
- Uses Supplementary Protection Certificates (SPCs) to promote antimicrobial research;
- Ensures continuous supply and EU-wide launch within two years of marketing authorization (“access conditionality”).
These extensions may be cumulative, potentially increasing total protection up to 12 or even 13 years in exceptional cases.
This marks a cultural shift: “access in exchange for exclusivity.”
Innovation is no longer rewarded merely for novelty, but for clinical proof and equitable availability to all EU patients.
Implications for clinical research
The European new pharmaceutical legislation reaffirms the central role of comparative clinical trials in assessing therapeutic value.
Clinical studies are no longer just a scientific obligation — they become a regulatory lever influencing data protection duration.
For sponsors, this means:
- Integrating head-to-head trials earlier in development against standard treatments;
- Designing protocols that demonstrate clinical added value;
- Planning studies in a pan-European framework via the CTIS portal under Regulation (EU) 536/2014.
Pricing and access: a more unified but more demanding Europe
A direct link will now connect market access and exclusivity duration.
Marketing authorization holders must launch their medicines in all EU member states within a defined period, or risk losing part of their exclusivity rights.
This addresses two recurring issues:
- Launch delays in smaller or less profitable markets;
- Supply shortages affecting continuity of care.
For market access teams, this reform requires closer coordination among the EMA, HAS, CEPS, and national pricing authorities to anticipate regulatory timelines, patient access volumes, and reimbursement strategies.
What impact on European innovation?
The EU seeks to reassert its position in the global pharmaceutical race, competing with the United States and Asia, where R&D timelines are shorter and protection systems more flexible.
If balanced correctly, this reform could enhance Europe’s attractiveness for innovation by aligning R&D protection, early access, and regulatory efficiency.
Rather than a “reduction” in protection, this represents a redefinition of competitiveness conditions for the European pharmaceutical ecosystem.
If you would like to receive regularly our articles, please subscribe here
Key sources and further reading
- Council of the European Union – Pharma Package: Council agrees its position (June 2025)
- European Commission – Pharmaceutical Strategy for Europe (updated 2025)
- Hogan Lovells LLP – EU Pharma Law Package: Council position on regulatory exclusivity reduction (2025)
- Crowell & Moring LLP – Comparison of Commission, Parliament and Council positions on data exclusivity (2025)
- Baker McKenzie – Council clears path to trilogue on pharma package (2025)
- Reuters – EU lawmakers vote to extend exclusivity period for new medicines (March 2024)
